-+ 0.00%
-+ 0.00%
-+ 0.00%

Biogen Q1 FY26 GAAP EPS jumps 31% to $2.15; revenue climbs 2% to $2.5 billion

PUBT·04/29/2026 10:01:45
Listen to the news
Biogen Q1 FY26 GAAP EPS jumps 31% to $2.15; revenue climbs 2% to $2.5 billion
  • Biogen posted Q1 2026 net income of USD 319.5 million, up 33%.
  • Revenue rose 2% to USD 2.48 billion.
  • GAAP diluted EPS climbed 31% to USD 2.15.
  • LEQEMBI global in-market sales jumped 74% to USD 168 million; SPINRAZA global revenue fell 12% to USD 374 million.
  • Biogen highlighted a proposed acquisition of Apellis Pharmaceuticals, expected to be accretive in 2027, and guided for 2026 non-GAAP diluted EPS of USD 14.25 to USD 15.25 with revenue projected to decline by a mid-single digit percentage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Biogen Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.